Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$1.08.

  • vTv Therapeutics' EPS (Basic) fell 2272.73% to -$1.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.27, marking a year-over-year increase of 2781.46%. This contributed to the annual value of -$3.2 for FY2024, which is 6705.39% up from last year.
  • According to the latest figures from Q3 2025, vTv Therapeutics' EPS (Basic) is -$1.08, which was down 2272.73% from -$0.92 recorded in Q2 2025.
  • vTv Therapeutics' 5-year EPS (Basic) high stood at -$0.01 for Q2 2021, and its period low was -$9.78 during Q4 2022.
  • In the last 5 years, vTv Therapeutics' EPS (Basic) had a median value of -$0.88 in 2024 and averaged -$1.8.
  • Within the past 5 years, the most significant YoY rise in vTv Therapeutics' EPS (Basic) was 8571.43% (2021), while the steepest drop was 2740000.0% (2021).
  • vTv Therapeutics' EPS (Basic) (Quarter) stood at -$8.19 in 2021, then decreased by 19.41% to -$9.78 in 2022, then surged by 82.92% to -$1.67 in 2023, then skyrocketed by 62.29% to -$0.63 in 2024, then crashed by 71.51% to -$1.08 in 2025.
  • Its last three reported values are -$1.08 in Q3 2025, -$0.92 for Q2 2025, and -$0.77 during Q1 2025.